Atomic AI
Business Services · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
329 Oyster Point Blvd, South San Francis...Website
www.atomic.aiRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
2
1
1
1
1
About Atomic AI
Atomic AI specializes in AI-driven RNA drug discovery, utilizing advanced machine learning and structural biology to develop RNA-targeted small molecules and RNA-based medicines. Their proprietary research and development platform features state-of-the-art deep learning models complemented by in-house wet-lab assays for enhanced drug discovery. They aim to address significant health challenges by creating highly potent and selective therapeutics. Their intended clients likely include pharmaceutical companies and research institutions focused on innovative drug development.Explore more
Atomic AI Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Atomic AI your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Atomic AI has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Atomic AI launches new products
Funding: Get notified immidiatlly once Atomic AI has new funding data
Click to see if Atomic AI had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Atomic AI
Earning: See what the market has to say on Atomic AI recently announced quarterly report
Atomic AI, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Check out if Atomic AI is spiking on competitors!
Recommended Actions
Reach out to Masked Content who joined Atomic AI as Masked Content
Find more new buyers
Compare Similar Companies to Atomic AI
Compare insights from companies similar to Atomic AI, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Atomic AI is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Atomic AI is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Atomic AI.
Atomic AI financials insights
Gather financial insights about Atomic AI, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2023
Series A
$35M
Atomic AI Tech Stack
A closer look at the technologies used by Atomic AI
See more technologies
Most Recent Scoops
Facilities Relocation / Expansion
Atomic AI is planning to move offices in January 2026. The move will impact employees at the existing office located at 151 Oyster Point Blvd, 3rd Floor, South San Francisco, CA.
Facilities Relocation/Expansion
Event
Product Marketing, Events, Learning & Development, Software, Bioengineering, Pharmaceuticals, Public Health, Field /Outside Sales, Field Marketing, Healthcare Technology, Patient Experience
Facilities Relocation / Expansion
Atomic AI is planning to move offices in September 2025. The move will impact employees at the existing office located at 151 Oyster Point Blvd, 3rd Floor, South San Francisco, CA.
Facilities Relocation/Expansion
Open Position
Hiring Plans
Atomic AI News & Media
Atomic AI Creates First Large Language Model Using Chemical Mapping Data to Optimize RNA Therapeutic Development
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atomic AI, a biotechnology company fusing cutting-edge machine learning with state-of-the-art structural biology to unlock RNA drug discovery, announced that the Company has created the first large language model (LLM) leveraging chemical mapping data. In a preprint paper published on bioRxiv, Atomic AI describes its proprietary ATOM-1™ platform component, a foundation model that can accurately predict the structure and function of RNA and help dramAtomic AI Adds Bristol Myers Squibb Veteran Dr. Manjunath Ramarao as Chief Scientific Officer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atomic AI, a biotechnology company fusing cutting-edge machine learning with state-of-the-art structural biology to unlock RNA drug discovery, today announced the addition of Manjunath “Manju” Ramarao, Ph.D., as Chief Scientific Officer. With over 20 years in the pharmaceutical industry, Dr. Ramarao brings extensive multidisciplinary experience in biopharmaceutical research and preclinical therapeutic development. “Since our inception in 2021, we'veAtomic AI Raises $35M in Series A Financing
Atomic AI, a San Francisco, CA-based biotechnology company combining machine learning with structural biology to unlock RNA drug discovery, raised $35M in Series A funding. The round was led by Playground Global, with participation from 8VC, Factory HQ, Greylock, NotBoring, AME Cloud Ventures, Nat Friedman, Doug Mohr, Neal Khosla, and Patrick Hsu. The company intends […] The post Atomic AI Raises $35M in Series A Financing appeared first on FinSMEs.Atomic AI Launches with $35M Series A
SAN FRANCISCO, CA, Atomic AI, a biotechnology company, launched with a $35 million Series A round led by Playground Global.
Read more news
Top Business Services Companies
See more top companies
Frequently Asked Questions Regarding Atomic AI
Sign Up For FreeTo access detailed company insights
Atomic AI specializes in AI-driven RNA drug discovery, utilizing advanced machine learning and structural biology to develop RNA-targeted small molecules and RNA-based medicines. Their proprietary research and development platform features state-of-the-art deep learning models complemented by in-house wet-lab assays for enhanced drug discovery. The... Read More
